Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.60 |
| ▸ | CDK2 | P24941 | 12/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | PAK4 | O96013 | 2/20 | 0.51 |
| ▸ | PRKCB | P05771 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25947656 | 0.89 | CDK2 (0.59) | NTRK1CDK2CCNA2CCNA1CDK1 | |
| SCHEMBL17872124 | 0.87 | NTRK1 (0.68) | NTRK1CDK2CCNA2CCNA1CDK1 | |
| SCHEMBL17872163 | 0.86 | NTRK1 (0.47) | NTRK1CDK2CCNA2CCNA1CDK1 | |
| SCHEMBL17872158 | 0.83 | KMT2A (0.43) | NTRK1 | |
| SCHEMBL17872129 | 0.80 | KMT2A (0.43) | — | |
| SCHEMBL17872102 | 0.79 | KMT2A (0.44) | NTRK1 | |
| SCHEMBL31256518 | 0.77 | PAK4 (0.41) | NTRK1CDK2CCNA2CCNA1PAK4 | |
| SCHEMBL22164976 | 0.77 | PAK4 (0.41) | NTRK1CDK2CCNA2CCNA1PAK4 | |
| SCHEMBL28738725 | 0.76 | CDK2 (0.60) | NTRK1CDK2CCNA2CCNA1CDK1 | |
| SCHEMBL28840124 | 0.75 | NTRK1 (1.00) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3236959-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190055248-A1 | INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| EP-3236959-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Dana Farber Cancer Institute, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016105528-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105528-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | NTRK1 438/4885CDK2 7/4885CCNA2 41/4885 |
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | NTRK1 438/4885CDK2 7/4885CCNA2 41/4885 |
| US-20190055248-A1 | INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | NTRK1 506/4885CDK2 7/4885CCNA2 43/4885 |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | NTRK1 438/4885CDK2 7/4885CCNA2 41/4885 |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | NTRK1 438/4885CDK2 7/4885CCNA2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.